Mutations in the ND2 subunit of mitochondrial complex I are sufficient to confer increased tumorigenic and metastatic potential to cancer cells

Marco-Brualla, Joaquín ; Al-Wasaby, Sameer ; Soler, Ruth ; Romanos, Eduardo ; Conde, Blanca (Universidad de Zaragoza) ; Justo-Méndez, Raquel ; Enríquez, José A. ; Fernández-Silva, Patricio (Universidad de Zaragoza) ; Martínez-Lostao, Luis (Universidad de Zaragoza) ; Villalba, Martín ; Moreno-Loshuertos, Raquel (Universidad de Zaragoza) ; Anel, Alberto (Universidad de Zaragoza)

Resumen: Multiprotein complexes of the mitochondrial electron transport chain form associations to generate supercomplexes. The relationship between tumor cell ability to assemble mitochondrial supercomplexes, tumorigenesis and metastasis has not been studied thoroughly. The mitochondrial and metabolic differences between L929dt cells, which lost matrix attachment and MHC-I expression, and their parental cell line L929, were analyzed. L929dt cells have lower capacity to generate energy through OXPHOS and lower respiratory capacity than parental L929 cells. Most importantly, L929dt cells show defects in mitochondrial supercomplex assembly, especially in those that contain complex I. These defects correlate with mtDNA mutations in L929dt cells at the ND2 subunit of complex I and are accompanied by a glycolytic shift. In addition, L929dt cells show higher in vivo tumorigenic and metastatic potential than the parental cell line. Cybrids with L929dt mitochondria in L929 nuclear background reproduce all L929dt properties, demonstrating that mitochondrial mutations are responsible for the aggressive tumor phenotype. In spite of their higher tumorigenic potential, L929dt or mitochondrial L929dt cybrid cells are sensitive both in vitro and in vivo to the PDK1 inhibitor dichloroacetate, which favors OXPHOS, suggesting benefits for the use of metabolic inhibitors in the treatment of especially aggressive tumors.

Idioma: Inglés

DOI: 10.3390/cancers11071027

Año: 2019

Publicado en: Cancers 11, 7 (2019), 1027 [20 pp.]
ISSN: 2072-6694

Factor impacto JCR: 6.126 (2019)

Categ. JCR: ONCOLOGY rank: 37 / 244 = 0.152 (2019) - Q1 - T1

Factor impacto SCIMAGO: 1.938 - Oncology (Q1) - Cancer Research (Q1)

Financiación: info:eu-repo/grantAgreement/ES/DGA/B31-17R
Financiación: info:eu-repo/grantAgreement/ES/MICINN/SAF2013-48626-C2-1-R
Financiación: info:eu-repo/grantAgreement/ES/MINECO/SAF2016-76338-R

Tipo y forma: Artículo (Versión definitiva)

Área (Departamento): Area Histología (Dpto. Anatom.Histolog.Humanas)
Área (Departamento): Área Inmunología (Dpto. Microb.Med.Pr.,Sal.Públ.)
Área (Departamento): Área Bioquímica y Biolog.Mole. (Dpto. Bioq.Biolog.Mol. Celular)